Randomized trials typically get top billing at ACR Convergence, but the past three years have seen “target trial emulations” land coveted plenary sessions and oral abstracts. These are not actually trials; instead, they are a new-ish approach to generating causal inferences from observational datasets. One particularly interesting oral presentation from ACR used this idea to investigate a critical question in ANCA associated vasculitis: should we be giving pulse dose steroids?
All News
Article
Article
Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms.
Article
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
https://t.co/pWu1eoiMVG https://t.co/k9aFvYhQSB
PMR: Spare The Steroids Please
Steroids remain both the cornerstone and the Achilles' heel of PMR management. We have aspirations of briskly tapering our patients once they have had their honeymoon phase with prednisone. But when Ms. Jones calls you with a reported second PMR https://t.co/dbrdVZRuoN
IgG4-RD in 3 Talks: Shorter Steroids, Earlier B-Cell Therapy
IgG4-related disease now has two phase 3 trials and its first dedicated treatment guidelines. Glucocorticoids remain the weak point.
https://t.co/pWu1eoiMVG https://t.co/yXXk0R4Rbs
Eric Dein
Tweet
Ab#2543 #ACR26 @RheumNow
Survey of US Academic Rheums on Opioid Rx
IMG trained - lower odds of opioid Rx
<5 yrs since training less likely to prescribe, 10-20 yrs OR 5.2, 20-30 yrs OR 6.7
60% felt opioids have role in rheum pain mgmt
70% feel pressured by pts
Dx: OA 41%, RA 28% https://t.co/Octn02lo3E
sheila
Tweet
Key takeaways for tx of hema manifestations in SLE:
- asymptomatic leucopenia doesn’t always require tx w/ steroids or IS in the absence of systemic manifestations
- r/o other etiologies
- comanage w/ hematologist
@RheumNow #ACR26 https://t.co/AXtDx4PZCO
Audrey Gibson
Tweet
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): A large real-world comparison found less steroid use with tirzepatide than semaglutide at 3 years: 27.2% vs 37.5%.@rheumnow #ACR2026 Abstract#2641
Audrey Gibson
Tweet
Jamshaid & Gomaa (Tirzepatide vs semaglutide cohort): Tirzepatide vs semaglutide in inflammatory arthritis: steroid use at 1 year was 19.1% vs 22.5% in matched cohorts. @rheumnow #ACR2026 Abstract#2641
Audrey Gibson
Tweet
Jamshaid et al: Tirzepatide vs semaglutide in inflammatory arthritis: 3-year steroid use was 27.2% vs 37.5%. Less treatment escalation is intriguing. @rheumnow #ACR2026 #ACRBest Abstract#2641
Akhil Sood MD, MS
Tweet
Which patients with started on GC are at increased risk of metabolic AEs?
Abstract 2754 found that baseline
- CHF (OR 3.21) > CKD (OR 1.86) strongest predictors
- MTX use lowered risk (OR 0.68)
@RheumNow #ACR26 https://t.co/ZLWCcypf4W
Richard Conway
Tweet
He et al. Tofacitinib + 4 weeks GC vs standard GC in PMR. Equal efficacy. Far less steroids, and less diabetes and osteoporosis in tofa group. @RheumNow #ACR26 Abstr#2106 #ACRbest https://t.co/acH8RauYln
Eric Dein
Tweet
Ab#2806 #ACR26 @RheumNow
Immune checkpoint inflamm arthr- inflamm patterns: peripheral IA/PMR/overlap
59% Persistent
B/l factors for persistence & DMARD/steroids >10mg: High CRP, Tenosynov (US/MRI), Peripheral IA pattern
Imaging improved model discrimination for dis persistence https://t.co/9TqObhFlWN
Brian Jaros, MD
Tweet
Vasculitis: beyond the guidelines session
When is a LoVAS prednisone taper an appropriate candidate?
NOT in patient with severe disease like DAH, renal involvement who were excluded from the study
A PEXIVAS regimen would be more appropriate in this case
@RheumNow #ACR26 https://t.co/vFY4aEgNvf
David Liew
Tweet
Wondering what you would use cheap generic tofacitinib for?
Well look no further. Find someone who would rather take steroids over tofa for their PMR & I will take them to meet my patients.
ITTG PMR study (open label RCT, n=104)
same people as EAST PMR
ABST2106 #ACR26 @RheumNow https://t.co/VQh1zprZbC
The shifting sands of glucocorticoid use in SLE
Despite the rapid development of emerging therapies for SLE, glucocorticoids remain an important component of disease management. "How well do our current corticosteroid prescribing habits align with current treatment guidelines?" https://t.co/kyZWVERLMP
Brian Jaros, MD
Tweet
Risk factors for relapse in IgG4-RD:
- high serum IgG4 level at dx
- multi-organ disease
- high serum IgE
- peripheral eosinophilia
Can this help us tailor steroid tapers and steroid sparing therapy?
@RheumNow #ACR26 https://t.co/QfJJFXFEBV
Richard Conway
Tweet
Kim et al. Target trial emulation. Add on pulse steroids (to RTX or CYC) in AAV. No benefit and higher infection risk. @RheumNow #ACR26 Abstr#0929 https://t.co/RPtIiP0XLN
